FDA Commissioner candidate Joseph Gulfo may have endeared himself to many agency reviewers with his call to end the breakthrough therapies program. But then again, his ideas for a multi-tiered approval system based on various types of evidence also could cause more concern.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?